Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Fentanyl 800microgram buccal films sugar free
0407020A0AABVBV
|
Fentanyl | Fentanyl | Central Nervous System | No data available |
|
Fentazin 2mg tablets
0402010Q0BBAAAC
|
Fentazin | Perphenazine | Central Nervous System | No data available |
|
Fentazin 4mg tablets
0402010Q0BBABAD
|
Fentazin | Perphenazine | Central Nervous System | No data available |
|
Feprapax 70mg tablets
0403010R0BDAAAA
|
Feprapax | Lofepramine hydrochloride | Central Nervous System | No data available |
|
Fetzima 40mg modified-release capsules
0403040AABBAAAA
|
Fetzima | Levomilnacipran | Central Nervous System | No data available |
|
Fetzima 80mg modified-release capsules
0403040AABBABAB
|
Fetzima | Levomilnacipran | Central Nervous System | No data available |
|
Filnarine SR 100mg tablets
0407020Q0BMADAH
|
Filnarine | Morphine sulfate | Central Nervous System | No data available |
|
Filnarine SR 10mg tablets
0407020Q0BMAAAK
|
Filnarine | Morphine sulfate | Central Nervous System | No data available |
|
Filnarine SR 200mg tablets
0407020Q0BMAEAG
|
Filnarine | Morphine sulfate | Central Nervous System | No data available |
|
Filnarine SR 30mg tablets
0407020Q0BMABAL
|
Filnarine | Morphine sulfate | Central Nervous System | No data available |
|
Filnarine SR 60mg tablets
0407020Q0BMACAI
|
Filnarine | Morphine sulfate | Central Nervous System | No data available |
|
Flu Relief with Decongestant capsules
0407010ABBGAAAC
|
Galpharm (Paracetamol/phenylephrine hydrochloride) | Paracetamol and phenylephrine hydrochloride | Central Nervous System | No data available |
|
Flu Strength Hot Lemon Pdrs 1g oral pdr sach (Bell,Sons&Co)
0407010H0CSABDG
|
Bell's (Paracetamol) | Paracetamol | Central Nervous System | No data available |
|
Flu Strength Hot Lemon Powders 1g oral pdr sach (Galpharm)
0407010H0CPAADG
|
Galpharm (Paracetamol) | Paracetamol | Central Nervous System | No data available |
|
Flunarizine 20mg tablets
0406000E0AAAEAE
|
Flunarizine dihydrochloride | Flunarizine dihydrochloride | Central Nervous System | No data available |
|
Flunitrazepam 1mg tablets
0401010I0AAAAAA
|
Flunitrazepam | Flunitrazepam | Central Nervous System | No data available |
|
Fluoxetine 10mg/5ml oral suspension
0403030E0AAAQAQ
|
Fluoxetine hydrochloride | Fluoxetine hydrochloride | Central Nervous System | No data available |
|
Fluoxetine 2.5mg/5ml oral liquid
0403030E0AAAGAG
|
Fluoxetine hydrochloride | Fluoxetine hydrochloride | Central Nervous System | No data available |
|
Fluoxetine 20mg/5ml oral suspension
0403030E0AAARAR
|
Fluoxetine hydrochloride | Fluoxetine hydrochloride | Central Nervous System | No data available |
|
Fluoxetine 2mg/5ml oral liquid
0403030E0AAAIAI
|
Fluoxetine hydrochloride | Fluoxetine hydrochloride | Central Nervous System | No data available |
|
Flupentixol 1mg/5ml oral solution
0403040F0AAAGAG
|
Flupentixol hydrochloride (Antidepressant) | Flupentixol hydrochloride | Central Nervous System | No data available |
|
Flupentixol 500micrograms/5ml oral liquid
0403040F0AAAFAF
|
Flupentixol hydrochloride (Antidepressant) | Flupentixol hydrochloride | Central Nervous System | No data available |
|
Fluphenazine 2.5mg tablets
0402010I0AAACAC
|
Fluphenazine hydrochloride | Fluphenazine hydrochloride | Central Nervous System | No data available |
|
Fluphenazine 5mg tablets
0402010I0AAADAD
|
Fluphenazine hydrochloride | Fluphenazine hydrochloride | Central Nervous System | No data available |
|
Fluphenazine decanoate 12.5mg/0.5ml inj ampoules
0402020L0AAAAAA
|
Fluphenazine decanoate | Fluphenazine decanoate | Central Nervous System | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.